Other cranial nerve disorders in other disorders

G6_CRAINOTH

cranial nerve palsy: Injury to any of the cranial nerves or their nuclei in the brain resulting in muscle weakness.

Suggest a new description

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

520210

1. Apply sex-specific rule

None

520210

2. Check conditions

None

520210

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

2 out of 7 registries used, show all original rules.

96

4. Check minimum number of events

None

96

5. Include endpoints

None

96

6. Filter based on genotype QC (FinnGen only)

96

Control definitions (FinnGen only)

Control exclude
G6_NERPLEX

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2

Case counts by codes

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 548 312 234
Only index persons 506 292 214
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 50.47 51.53 48.97
Only index persons 48.97 49.40 48.38

-FinnGen-

Key figures

All Female Male
Number of individuals 96 55 41
Unadjusted period prevalence (%) 0.02 0.02 0.02
Median age at first event (years) 47.98 46.40 50.09

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
84
Matched controls
839
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G53.2*D86.8
ICD-10 Finland
Multiple cranial nerve palsies in sarcoidosis
+∞
63.9
53
*
D86.8
ICD-10 Finland
Sarcoidosis of other and combined sites
207.5
49.1
47
5
D86.9
ICD-10 Finland
Sarcoidosis, unspecified
160.4
31.1
31
*
132
Kela drug reimbursment
Sarcoidosis
130.1
26.5
27
*
D86.0
ICD-10 Finland
Sarcoidosis of lung
97.5
25.6
27
*
G51.0
ICD-10 Finland
Bell palsy
+∞
20.7
19
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
17.7
19.7
32
28
TAB00
NOMESCO Finland
Lumbar puncture
31.6
19.1
25
11
G53.2
ICD-10 Finland
Multiple cranial nerve palsies in sarcoidosis
+∞
17.3
16
*
D86.2
ICD-10 Finland
Sarcoidosis of lung with sarcoidosis of lymph nodes
56.4
15.8
18
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
9.7
15.0
33
52
H02AB06
ATC
prednisolone; systemic
5.9
12.6
63
282
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
32.3
12.6
16
6
L04AX01
ATC
azathioprine; systemic
18.4
12.5
19
13
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
5.3
11.2
44
145
GD1AA
NOMESCO Finland
Thorax X-ray examination
5.0
11.1
54
222
H04.10
ICD-10 Finland
Dry eye syndrome
9.6
10.2
21
28
M05BA04
ATC
alendronic acid; oral
8.9
9.8
21
30
D86.1
ICD-10 Finland
Sarcoidosis of lymph nodes
27.6
9.2
12
5
G53.1
ICD-10 Finland
Multiple cranial nerve palsies in infectious and parasitic diseases classified elsewhere
+∞
8.5
8
*
D86.3
ICD-10 Finland
Sarcoidosis of skin
+∞
8.5
8
*
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
9.1
7.8
16
21
R20.2
ICD-10 Finland
Paraesthesia of skin
9.9
7.7
15
18
R42
ICD-10 Finland
Dizziness and giddiness
4.6
7.6
29
86
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
22.3
7.3
10
5
N03AX12
ATC
gabapentin; oral
5.2
7.0
22
53
TPH04
NOMESCO Finland
Cathetrisation of vein
4.0
6.7
29
97
G56.0
ICD-10 Finland
Carpal tunnel syndrome
15.9
6.6
10
7
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
75.2
6.5
7
*
I41.8*D86.8
ICD-10 Finland
Sarcoid myocarditis
75.2
6.5
7
*
M14.8*D86.8
ICD-10 Finland
Arthropathy in sarcoidosis
+∞
6.3
6
*
A02BC02
ATC
pantoprazole; systemic
3.5
6.3
64
402
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
6.8
6.2
15
26
XCK00
NOMESCO Finland
Perimetry
6.5
6.0
15
27

LabWAS

OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
16
13
14.57
16.45
1.5
1.2
—
—
—
0
0
51
237
3.46
8.30
10.9
5.6
—
—
—
0
0
68
381
3.69
8.12
10.8
6.4
0.6
0.6
e9/l
0.10
62
333
69
391
3.72
8.08
10.8
6.6
0.2
0.2
e9/l
0.47
63
348
68
382
3.67
8.06
10.8
6.4
0.0
0.0
e9/l
0.40
62
332
68
388
3.58
7.74
10.8
6.5
1.7
2.1
e9/l
0.74
61
348
10
7
15.73
6.55
1.2
1.1
—
—
—
0
0
22
73
3.61
5.83
3.3
1.8
333.8
383.7
nmol/l
0.66
22
66
9
8
12.25
5.41
2.8
3.9
59.9
67.1
%
—
9
8
9
8
12.25
5.41
2.7
2.0
4.0
6.5
e9/l
—
9
8
69
449
2.91
5.34
14.0
10.2
3.8
4.1
e9/l
0.57
62
395
7
6
12.44
4.34
1.6
1.2
—
—
—
0
0
47
274
2.40
4.25
4.2
3.6
17.3
33.5
ng/l
1.56
37
185
36
189
2.45
4.08
4.1
3.8
—
—
—
0
0
38
208
2.37
3.90
8.6
4.0
7.4
7.4
ph
0.07
12
43
7
8
9.32
3.84
2.0
1.4
—
—
—
0
0
40
227
2.31
3.75
1.9
2.1
122.4
174.6
u/l
1.21
35
213
6
6
10.55
3.54
3.0
1.7
—
—
—
0
0
37
208
2.27
3.51
6.2
2.8
—
—
—
0
0
45
278
2.16
3.36
14.1
7.6
1.3
1.2
inr
—
10
89
21
96
2.52
3.11
1.6
1.4
406.7
387.4
titre
—
6
19
69
520
2.16
2.90
8.5
3.8
—
—
—
0
0
7
14
5.30
2.78
3.4
2.9
—
—
—
0
0
5
6
8.70
2.78
1.8
1.2
—
—
—
0
0
34
201
2.07
2.75
7.4
6.0
—
—
—
0
0
38
235
2.02
2.71
4.5
3.6
4.7
8.4
mg/mmol
0.46
28
154
35
212
2.02
2.63
3.9
3.0
45.8
354.3
mg/l
0.51
28
146
20
97
2.34
2.60
2.8
2.2
2.3
2.5
g/l
0.43
20
87
50
352
1.88
2.37
13.4
9.4
0.0
0.0
e9/l
0.47
44
290
9
29
3.32
2.29
1.7
2.1
—
—
—
0
0
15
71
2.32
2.05
2.7
4.5
—
—
—
0
0
52
394
1.70
1.75
6.4
4.6
0.0
0.0
estimate
—
9
75
43
310
1.70
1.74
3.7
3.2
—
—
—
0
0
5
13
3.99
1.73
5.0
5.4
—
—
—
0
0
52
395
1.69
1.73
4.9
3.3
0.0
0.0
estimate
—
9
77
6
19
3.30
1.69
1.7
1.5
—
—
—
0
0
16
85
2.06
1.67
1.9
1.3
—
—
—
0
0
22
132
1.86
1.64
6.1
3.0
21.9
143.0
ng/l
1.31
16
95
52
400
1.65
1.61
4.9
3.3
0.0
0.0
estimate
—
10
73
43
315
1.66
1.61
2.3
2.1
—
—
—
0
0
23
142
1.81
1.57
1.1
1.2
1.4
4.3
u/ml
—
10
56
5
15
3.46
1.54
1.6
1.8
—
—
—
0
0
24
151
1.79
1.54
3.7
2.4
5.9
3.9
e6/l
0.57
24
138
7
28
2.61
1.48
12.7
9.1
—
—
—
0
0
14
74
2.04
1.48
3.3
3.3
1.9
1.8
%
0.36
14
68
5
16
3.24
1.45
1.0
2.3
—
—
—
0
0
12
60
2.14
1.45
1.3
1.2
—
—
—
0
0
7
29
2.52
1.42
4.1
1.6
—
—
—
0
0
15
83
1.96
1.41
1.3
1.2
—
—
—
0
0
15
84
1.93
1.36
1.5
1.4
—
—
—
0
0
12
63
2.03
1.29
5.9
3.1
—
—
—
0
0
28
193
1.64
1.29
5.0
2.5
—
—
—
0
0
11
56
2.09
1.28
4.5
3.7
—
—
—
0
0
10
49
2.16
1.27
1.1
1.7
—
—
—
0
0
42
324
1.53
1.19
4.5
2.6
161.1
111.9
ug/l
0.68
42
300
16
96
1.80
1.19
2.6
1.8
—
—
—
0
0
8
40
2.09
1.15
6.1
4.2
—
—
—
0
0
19
122
1.69
1.13
1.5
1.9
—
—
—
0
0
87
803
1.89
1.11
22.3
12.3
14.8
23.0
mg/l
2.49
77
616
9
45
2.10
1.08
1.8
2.4
1.6
1.3
%
—
9
45
7
33
2.21
1.08
1.1
1.2
—
—
—
0
0
9
46
2.05
1.07
6.2
1.5
—
—
—
0
0
38
293
1.49
1.06
2.1
1.9
94.0
93.4
pmol/l
0.03
24
147
30
220
1.53
1.06
5.0
3.0
—
—
—
0
0
10
54
1.95
1.01
2.1
3.5
128.2
129.6
g/l
—
10
54
22
152
1.58
1.00
1.1
1.2
11.5
37.2
iu/ml
—
5
49
30
224
1.49
0.96
4.4
3.4
—
—
—
0
0
26
189
1.52
0.95
4.6
3.2
94.9
94.0
%
0.06
26
184
28
209
1.48
0.90
10.5
5.9
—
—
—
0
0
25
185
1.48
0.83
2.1
1.6
8.0
1.1
mg/l
0.42
19
149
6
34
1.81
0.77
1.2
1.1
—
—
—
0
0
28
216
1.42
0.75
2.1
1.9
—
—
—
0
0
7
39
1.86
0.74
1.4
1.2
—
—
—
0
0
9
58
1.61
0.72
2.9
8.6
—
—
—
0
0
15
103
1.54
0.70
1.1
1.2
—
—
—
0
0
5
27
1.90
0.69
1.0
1.3
—
193.5
—
0
14
14
95
1.55
0.69
1.2
1.5
—
—
—
0
0
22
167
1.41
0.64
1.3
1.2
0.4
2.2
u/ml
—
7
49
12
82
1.53
0.57
1.4
1.8
—
—
—
0
0
13
91
1.50
0.56
1.1
1.5
—
—
—
0
0
7
106
0.63
0.52
1.0
1.4
—
—
—
0
0
7
49
1.46
0.47
10.3
4.6
—
—
—
0
0
8
61
1.34
0.41
1.5
1.8
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
21
171
1.29
0.40
5.7
3.6
1.0
1.0
kg/l
—
5
20
26
218
1.26
0.40
5.4
3.4
0.0
0.0
estimate
—
10
73
9
67
1.38
0.39
2.7
3.7
—
—
—
0
0
11
139
0.76
0.29
1.5
2.3
2.4
2.4
mmol/l
0.00
11
125
10
78
1.31
0.25
2.2
1.4
—
—
—
0
0
16
189
0.82
0.25
1.2
1.4
—
—
—
0
0
5
41
1.23
0.22
3.2
2.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
81
830
0.85
0.17
5.8
4.7
2.8
2.8
mmol/l
0.07
76
771
8
96
0.82
0.14
13.9
24.7
—
1.4
—
0
17
74
757
0.90
0.11
23.0
12.5
39.6
40.6
%
0.40
46
577
5
43
1.17
0.10
2.6
10.2
93.5
94.0
%
—
5
43
86
847
1.15
0.09
20.1
11.3
—
—
—
0
0
6
58
1.04
0.08
1.7
1.3
—
—
—
0
0
8
74
1.09
0.08
1.6
1.4
—
—
—
0
0
59
575
1.07
0.07
4.3
3.5
—
—
—
0
0
80
790
1.08
0.04
4.5
3.9
1.5
1.3
mmol/l
1.06
75
737
77
760
1.07
0.04
8.5
5.3
41.7
39.5
mmol/mol
1.12
72
718
86
858
1.02
0.00
25.1
14.4
77.2
77.2
umol/l
0.00
86
858
79
792
0.99
0.00
4.8
4.4
6.0
5.9
mmol/l
0.16
73
731
36
357
1.01
0.00
3.5
2.7
—
—
—
0
0
19
186
1.03
0.00
5.3
3.3
—
—
—
0
0
0
5
0.00
0.00
0.0
5.0
—
38.0
—
0
5
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
2.4
—
3.3
—
0
5
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.0
—
7.3
—
0
6
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
3.1
—
0.8
—
0
9
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
2.5
—
12.6
—
0
8
0
6
0.00
0.00
0.0
1.2
—
13.5
—
0
6
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
2.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.8
—
—
—
0
0

Mortality – FinRegistry

Association

Association between endpoint G6_CRAINOTH and mortality.

Females

Parameter HR [95% CI] p-value
G6_CRAINOTH 2.04 [1.48, 2.81] < 0.001
Birth year 0.993 [0.98, 1.0] 0.114

During the follow-up period (1.1.1998 — 31.12.2019), 57 out of 292 females with G6_CRAINOTH died.

Males

Parameter HR [95% CI] p-value
G6_CRAINOTH 1.899 [1.36, 2.64] < 0.001
Birth year 0.989 [0.98, 1.0] 0.037

During the follow-up period (1.1.1998 — 31.12.2019), 54 out of 223 males with G6_CRAINOTH died.

Mortality risk

Mortality risk for people of age

years, who have G6_CRAINOTH.

N-year risk Females Males
1 0.163% 0.463%
5 1.165% 2.375%
10 2.897% 6.245%
15 5.219% 11.758%
20 9.075% 18.899%

Relationships between endpoints

Index endpoint: G6_CRAINOTH – Other cranial nerve disorders in other disorders

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data